Welcome to our dedicated page for Pds Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology Corporation stock.
PDS Biotechnology Corporation (NASDAQ: PDSB) delivers innovative immunotherapies through its Versamune® platform, targeting cancers and infectious diseases. This news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and corporate developments.
Access primary-source press releases and curated analysis covering PDSB's clinical trials, partnership announcements, and financial disclosures. Track progress across key areas: Phase II/III oncology studies, FDA communications, and strategic collaborations enhancing their nanoparticle-based therapies.
Our repository ensures you stay informed about critical developments in HPV-associated cancer treatments, combination therapy research, and infectious disease vaccine progress. Bookmark this page for direct access to PDSB's verified updates, eliminating the need to scour multiple sources.
PDS Biotechnology Corporation (Nasdaq: PDSB) released a white paper on its Versamune® T-cell activating technology, highlighting its potential in cancer treatment. The technology aims to enhance the body’s immune response against tumors, addressing limitations seen in existing immunotherapies. Versamune® has shown superior induction of tumor-recognizing T-cells in preclinical studies, promising a favorable safety profile. PDS Biotech's pipeline focuses on antigens for challenging solid tumors. CEO Dr. Frank Bedu-Addo emphasizes a commitment to developing innovative cancer therapies.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the approval of inducement stock options covering 202,800 shares to newly appointed CFO Seth Van Voorhees. The options have an exercise price of $2.28, the closing stock price on January 4, 2021. Vested over four years, these awards align with PDSB’s 2019 Inducement Plan aimed at attracting new employees. PDS Biotechnology focuses on developing immunotherapies using its proprietary Versamune® technology to treat cancer and infectious diseases.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced that CEO Dr. Frank Bedu-Addo will present at H.C. Wainwright’s BioConnect virtual conference. The presentation will be available on-demand starting January 11, 2021, at 6:00 AM ET. PDS Biotech is focused on developing innovative immunotherapy treatments and vaccines utilizing its proprietary Versamune® technology, which aims to enhance the immune system's ability to recognize and destroy disease cells. A replay will be accessible in the investor relations section of the company's website.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced promising results from preclinical studies of its Versamune® T-cell activating platform, showing significant antibody induction against SARS-CoV-2 with low antigen doses. The research conducted by the Icahn School of Medicine indicates Versamune's potential for a cost-effective COVID-19 vaccine, PDS0203, which is in development with Farmacore. The study highlights rapid immune responses, including strong neutralizing antibodies and T-cell activation. This positions PDSB favorably in the competitive vaccine landscape.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the appointment of Seth Van Voorhees, Ph.D. as the new Chief Financial Officer, effective January 1, 2021. Dr. Van Voorhees brings extensive experience in corporate finance, investment banking, and licensing, previously serving as CFO at Research Frontiers and American Pacific. CEO Frank Bedu-Addo highlighted this as a pivotal moment for the company, with opportunities ahead leveraging its proprietary Versamune® technology platform. The transition follows the interim role of Michael King, whose contributions were acknowledged.
PDS Biotechnology Corporation (Nasdaq: PDSB) has been granted U.S. Patent No. 10,828,364 for its Versamune® platform. This patent includes methods for reducing myeloid derived suppressor cell (MDSC) populations, which hinder immune responses, via cationic lipid vaccine compositions. The patent solidifies protections for the Versamune® platform, enhancing its potential for improved clinical outcomes in ongoing mid-stage trials of PDS0101, targeting HPV-related cancers. Additionally, the U.S. Government retains certain rights due to prior support from the National Cancer Institute.
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company, announced that CEO Dr. Frank Bedu-Addo will present at the virtual Fall Investor Summit on November 16, 2020, at 10:30 AM Eastern Time. This event features 75 companies and connects them with over 300 institutional and retail investors. A replay of the presentation will be available in the investor relations section of the Company’s website. PDS Biotech specializes in cancer therapies and infectious disease vaccines using its proprietary Versamune technology.
PDS Biotechnology Corporation (Nasdaq: PDSB) reported Q3 2020 financial results, revealing a net loss of approximately $3.9 million, or $0.23 per share, a decrease from a $5.8 million loss in Q3 2019. R&D expenses rose by 12% to $2.1 million, while general and administrative costs dropped by 40% to $1.8 million. The company successfully raised $19 million in a public offering and initiated several Phase 2 trials for its investigational drug PDS0101. As of September 30, 2020, cash reserves stood at $33.5 million.
PDS Biotech has prioritized the clinical development of PDS0203, a Versamune®-based COVID-19 vaccine, following a successful meeting with Brazil's drug regulatory agency, ANVISA. The vaccine aims to elicit strong immune responses, showing a 30-45 fold increase in T-cell activation compared to standard vaccines. PDS Biotech and Farmacore plan to begin human trials in the first half of 2021, backed by promising preclinical data. Both companies will collaborate on regulatory efforts, with Farmacore leading in Brazil.
PDS Biotechnology Corporation has launched the VERSATILE-002 Phase 2 trial, assessing the combination of PDS0101 and KEYTRUDA® for first-line treatment of recurrent or metastatic head and neck cancer. This multi-center trial aims to enroll around 100 patients across 25 sites in the U.S., with the University of Tennessee Medical Center as the first site. The study evaluates the efficacy and safety of PDS0101, targeting HPV-associated cancers. The primary endpoint is the objective response rate at nine months. This trial marks a significant step in the collaboration with Merck.
